Anova analysis of cancer cell line profiling data reveals a strong association with ABL-dependent cell growth for all CML-approved inhibitors, except bosutinib (Figure 5C). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.